健康元：健康元药业集团股份有限公司2022年半年度报告（英文版）.PDF

《健康元：健康元药业集团股份有限公司2022年半年度报告（英文版）.PDF》由会员分享，可在线阅读，更多相关《健康元：健康元药业集团股份有限公司2022年半年度报告（英文版）.PDF（259页珍藏版）》请在得力文库 - 分享文档赚钱的网站上搜索。

1、lnterim Report 2022为明天 为健康Joincare Pharmaceutical Group Industry Co.,Ltd.FOR THE HEALTH FOR THE FUTUREStock abbreviation:健康元Stock code:600380【Mission】For the health,For the future【Vision】Attentively Develop High-quality Medicines and lnnovative Medicines【Core Values】Putting People at the first place

2、,Valuing Workmanship and Quality,Pursuing Innovation and lntegrity,Promoting Cooperation and SharingI The Board of Directors(the“Board”),the Board of Supervisors and directors,supervisors and senior management of the Company hereby warrant the truthfulness,accuracy and completeness of the contents o

3、f the interim report(the“Report”),and that there are no false representations,misleading statements or material omissions contained in the Report,and severally and jointly accept responsibility.II All the directors of the Company attended the Board meeting.III The interim report of the Company is un

4、audited.IV Mr.Zhu Baoguo(朱保国),the person-in-charge of the Company,and Mr.Qiu Qingfeng(邱庆丰),the person-in-charge of the Companys accounting work and the person-in-charge of the accounting department(the head of the accounting department),declare that they hereby warrant the truthfulness,accuracy and

5、completeness of the financial statements contained in the Report.V Profit distribution plan or plan for conversion of capital reserve to share capital approved by the Board during the Reporting PeriodNot applicableVI Risk declaration for the forward-looking statements Applicable N/AThe Report contai

6、ns forward-looking statements which involve the future plans,development strategies,etc.of the Company,yet do not constitute substantive undertakings of the Company to investors.Investors should exercise caution prior to making investment decisions.VII Whether there is non-operating use of funds by

7、the controlling shareholder and their related parties NoVIII Whether there is a violation of the prescribed decision-making procedures to provide external guarantees NoIX Whether more than half of directors cannot warrant the truthfulness,accuracy and completeness of the Report disclosed by the Comp

8、anyNoX Significant risk warningsThere is no exceptionally significant risk that will have a material impact on the productions and operations of the Company during the Reporting Period.The Company has described various risks related to productions and operations that the Company may face and the cor

9、responding response measures taken.Please refer to“Risks”in Chapter 3“Management Discussion and Analysis”.XI Others Applicable N/AXII The Report is prepared in both Chinese and English.In case of any discrepancies between two versions,the Chinese version shall prevail.Important NoticeFOR THE HEALTH

10、FOR THE FUTURE1lnterim Report 2022Table of ContentsFinancial Highlights 2Chapter 1 Definitions 4Chapter 2 Company Profile and Major Financial Indicators 7Chapter 3 Management Discussion and Analysis 12Chapter 4 Corporate Governance 35Chapter 5 Environmental and Corporate Social Responsibility 40Chap

11、ter 6 Major Events 67Chapter 7 Changes in Equity and Shareholders 82Chapter 8 Information on Preferred Shares 87Chapter 9 Information on Bonds 89Chapter 10 Financial Statements 91List of documents available for inspectionThe Financial Statements signed and sealed by the person-in-charge of the Compa

12、ny,the person-in-charge of the Companys accounting work and the person-in-charge of the accounting department(the head of the accounting department)The original copies of all documents and announcements of the Company which have been disclosed to the public on the website designated by CSRC during t

13、he Reporting Period2Joincare Pharmaceutical Group Industry Co.,Ltd.85.650.42350.42328.018.0478.350.35140.35046.875.981.Major financial indicators(RMB100 million)2.Principal businesses(RMB100 million)Reporting PeriodSame Period of Last YearRevenuesEPS(RMB/share)EPS-Diluted(RMB/share)Net profit attrib

14、utable to shareholders of the listed companyNet profit attributable to shareholders of the listed company after deducting the extraordinary gain or lossChemical pharmaceuticalsTraditional Chinese medicineHealth care productsDiagnostic reagents and equipmentChemical APIs and intermediates6.06%5.144.0

15、7%3.460.64%0.5556.51%47.9932.64%27.72 9.31%16.57%34.47%20.52%20.78%Revenues from principal businesses:84.92Financial Highlights3Interim Report 20223.Segment growth(RMB100 million)Chemical pharmaceuticalsBy segmentBy productRevenueRevenueGrowthGrowthGastroenterologyChemical APIs and intermediates17.8

16、127.72-8.16%6.82%3.28%259%36.26%22.70%-18.74%-11.43%13.445.146.833.465.612.64PsychiatryRespiratoryAnti-infectionGonadorelin hormoneDiagnostic reagents and equipmentTraditional Chinese medicine1Definitions5Interim Report 2022In this Report,unless the context otherwise requires,the following expressio

17、ns shall have the following meanings:Definitions of common termsCSRCRefers toChina Securities Regulatory CommissionSSERefers toShanghai Stock ExchangeSZSERefers toShenzhen Stock ExchangeBaiyeyuan or the Controlling ShareholderRefers toShenzhen Baiyeyuan Investment Co.,Ltd.*(深圳市百业源投资有限公司)Company or t

18、he CompanyRefers toJoincare Pharmaceutical Group Industry Co.,Ltd.*(健康元药业集团股份有限公司)GDRRefers toGlobal Depositary ReceiptsGMPRefers toGood Manufacturing PracticeGSPRefers toGood Supply PracticeBERefers toBioequivalenceBLARefers toBiologics License ApplicationWHORefers toWorld Health OrganizationCDERef

19、ers toCenter for Drug EvaluationEUARefers toEmergency Use AuthorizationsKOLRefers toKey Opinion LeaderMVRRefers toMechanical Vapor RecompressionQCRefers toQuality ControlLivzon GroupRefers toLivzon Pharmaceutical Group Inc.*(丽珠医药集团股份有限公司)Haibin PharmaRefers toShenzhen Haibin Pharmaceutical Co.,Ltd.*

20、(深圳市海滨制药有限公司)Xinxiang HaibinRefers toXinxiang Haibin Pharmaceutical Co.,Ltd.*(新乡海滨药业有限公司)Taitai PharmaceuticalRefers toShenzhen Taitai Pharmaceutical Co.,Ltd.*(深圳太太药业有限公司)Joincare HaibinRefers toJoincare Haibin Pharmaceutical Co.,Ltd.*(健康元海滨药业有限公司)Taitai GenomicsRefers toShenzhen Taitai Genomics Inc

21、.Co.,Ltd.*(深圳太太基因工程有限公司)Jiaozuo JoincareRefers toJiaozuo Joincare Bio Technological Co.,Ltd.*(焦作健康元生物制品有限公司)Joincare Daily-UseRefers toJoincare Daily-Use&Health Care Co.,Ltd.*(健康元日用保健品有限公司)TopsinoRefers toTopsino Industries Limited*(天诚实业有限公司)Fenglei Electric PowerRefers toShenzhen Fenglei Electric P

22、ower Investment Co.,Ltd.*(深圳市风雷电力投资有限公司)Chapter 1Definitions6Joincare Pharmaceutical Group Industry Co.,Ltd.Definitions of common termsHealth PharmaceuticalRefers toHealth Pharmaceutical(China)Co.,Ltd.*(健康药业(中国)有限公司)Hiyeah IndustryRefers toShenzhen Hiyeah Industry Co.,Ltd.*(深圳市喜悦实业有限公司)Shanghai Fron

23、tierRefers toShanghai Frontier Health Pharmaceutical Technology Co.,Ltd.*(上海方予健康医药科技有限公司)Appraisal InstitutionRefers toGuangdong Taitai Forenstic Test Institute*(广东太太法医物证司法鉴定所)Hong Kong PharmaceuticalRefers toHong Kong Health Pharmaceutical Industry Company Limited*(香港健康药业有限公司)Health InvestmentRefer

24、s toHealth Investment Holdings Ltd.Joincare Special Medicine FoodRefers toJoincare(Guangdong)Special Medicine Food Co.,Ltd.*(健康元(广东)特医食品有限公司)Livzon MABRefers toLivzon MABPharm Inc.*(珠海市丽珠单抗生物技术有限公司)Livzon DiagnosticsRefers toZhuhai Livzon Diagnostics Inc.*(珠海丽珠试剂股份有限公司)Xinbeijiang PharmaceuticalRefe

25、rs toLivzon Group Xinbeijiang Pharmaceutical Manufacturing Inc.*(丽珠集团新北江制药股份有限公司)Ningxia PharmaceuticalRefers toLivzon Group(Ningxia)Pharmaceutical Manufacturing Co.,Ltd.*(丽珠集团(宁夏)制药有限公司)Gutian FuxingRefers toGutian Fuxing Pharmaceutical Co.,Ltd.*(古田福兴医药有限公司)Fuzhou FuxingRefers toLivzon Group Fuzhou

26、 Fuxing Pharmaceutical Co.,Ltd.*(丽珠集团福州福兴医药有限公司)Livzon HechengRefers toZhuhai FTZ Livzon Hecheng Pharmaceutical Manufacturing Co.,Ltd.*(珠海保税区丽珠合成制药有限公司)Livzon LiminRefers toLivzon Group Limin Pharmaceutical Manufacturing Factory*(丽珠集团利民制药厂)Livzon Pharmaceutical FactoryRefers toLivzon Group Livzon Ph

27、armaceutical Factory*(丽珠集团丽珠制药厂)Shanghai LivzonRefers toShanghai Livzon Pharmaceutical Manufacturing Co.,Ltd.*(上海丽珠制药有限公司)Sichuan GuangdaRefers toSichuan Guangda Pharmaceutical Manufacturing Co.,Ltd.*(四川光大制药有限公司)Jiaozuo HechengRefers toJiaozuo Livzon Hecheng Pharmaceutical Manufacturing Co.,Ltd.*(焦作

28、丽珠合成制药有限公司)Jinguan Electric PowerRefers toJiaozuo Jinguan Jiahua Electric Power Co.,Ltd.*(焦作金冠嘉华电力有限公司)Tianjin TongrentangRefers toTianjin Tongrentang Group Co.,Ltd.*(天津同仁堂集团股份有限公司)LivzonBioRefers toZhuhai Livzon Biotechnology Co.,Ltd.*(珠海市丽珠生物医药科技有限公司)National COVID-19 Vaccine Working GroupRefers t

29、oWorking group for vaccine development under the State Council joint prevention and control mechanism against COVID-19COVID-19Refers toA new coronavirus(SARS-CoV-2)COVID-19 pandemic or pandemicRefers toThe outbreak of the disease caused by a new coronavirus called SARS-CoV-2Ruihua Certified Public A

30、ccountantsRefers toRuihua Certified Public Accountants(Special General Partnership)Reporting PeriodRefers toFrom 1 January 2022 to 30 June 2022End of the Reporting PeriodRefers to30 June 2022Currency or unitRefers toRMB unless otherwise specified*For identification purpose only2Company Profile and M

31、ajor Financial Indicators8Joincare Pharmaceutical Group Industry Co.,Ltd.I Company profileChinese name of the Company健康元药业集团股份有限公司Abbreviation of the Chinese name健康元English name of the CompanyJoincare Pharmaceutical Group Industry Co.,Ltd.Abbreviation of the English nameJoincareLegal representative

32、of the CompanyZhu BaoguoII Contact persons and contact detailsBoard SecretaryRepresentative of Securities AffairsNameZhao Fengguang(赵凤光)Li Hongtao(李洪涛),Luo Xiao(罗逍)AddressJoincare Pharmaceutical Group Building,No.17,Langshan Road,North District,Hi-tech Zone,Nanshan District,ShenzhenJoincare Pharmace

33、utical Group Building,No.17,Langshan Road,North District,Hi-tech Zone,Nanshan District,ShenzhenTelephone0755-86252656,0755-862523880755-86252656,0755-86252388Fax0755-862521650755-86252165E-,III Introduction of the Companys basic informationRegistered addressJoincare Pharmaceutical Group Building,No.

34、17,Langshan Road,North District,Hi-tech Zone,Nanshan District,ShenzhenHistorical changes in registered addressRegistered at B5,Hengfeng Industrial City,Hezhou Community,Huangtian Village,Xinan Town,Baoan County on 18 December 1992Changed its registered address to 4-5/F,Dongpeng Building,Shangmeilin

35、Industrial Area,Futian District,Shenzhen on 25 May 1994Changed its registered address to 24/F,Block B,Fujian Building,Caitian South Road,Futian District,Shenzhen on 4 July 1995Changed its registered address to 23/F,Diwang Building,Shun Hing Square,No.333,Shennan East Road,Shenzhen on 20 June 1997Cha

36、nged its registered address to Taitai Pharmaceutical Industrial Building,the 5th Industrial Area,Nanshan District,Shenzhen on 22 September 2000Changed its registered address to 23/F,Diwang Building,Shun Hing Square,No.5002,Shennan East Road,Luohu District,Shenzhen on 4 June 2003Changed its registere

37、d address to Joincare Pharmaceutical Group Building,No.17,Langshan Road,North District,Hi-tech Zone,Nanshan District,Shenzhen on 29 January 2008Changed its registered address to Joincare Pharmaceutical Group Building,No.17,Langshan Road,North District,Hi-tech Zone,Nanshan District,Shenzhen on 27 Nov

38、ember 2012Office addressJoincare Pharmaceutical Group Building,No.17,Langshan Road,North District,Hi-tech Zone,Nanshan District,ShenzhenPostal code of Office address518057Website http:/E-Index for query of changes during the Reporting PeriodThere was no change during the Reporting PeriodChapter 2Com

39、pany Profile and Major Financial Indicators9Interim Report 2022IV Introduction of changes in information disclosure and places for inspectionName of designated newspapers for information disclosure by the CompanyChina Securities Journal,Securities Times,Securities Daily,and Shanghai Securities NewsW

40、ebsite for publication of the interim report http:/Place for inspection of the interim report of the CompanyOffice address of the CompanyIndex for query of changes during the Reporting PeriodThere was no change during the Reporting PeriodV Company stock profileClass of stockListed onStock Abbreviati

41、onStock codeStock abbreviation prior to changeA ShareShanghai Stock Exchange健康元600380太太药业,S健康元VI Other relevant information Applicable N/AVII Principal accounting data and financial indicators of the Company(I)Principal accounting dataUnit:YuanCurrency:RMBPrincipal accounting dataReporting Period Sa

42、me Period Last YearIncrease/(decrease)for the Reporting Period as compared to the same period last year(From January to June)(%)Revenues8,564,945,285.557,835,372,274.669.31Net profit attributable to Shareholders of the listed company801,268,519.50687,347,494.5316.57Net profit attributable to Shareho

43、lders of the listed company after deducting the extraordinary gain or loss803,994,432.03597,892,327.4334.47Net cash flow from operating activities1,902,953,224.79745,787,513.36155.16End of the Reporting PeriodEnd of the Last YearIncrease/decrease as at the end of the Reporting Period as compared to

44、the end of last year(%)Net assets attributable to Shareholders of the listed company11,922,666,818.9311,820,293,656.690.87Total assets32,181,512,667.2931,103,900,389.293.4610Joincare Pharmaceutical Group Industry Co.,Ltd.(II)Major Financial IndicatorsMajor Financial IndicatorsReporting Period Same P

45、eriod Last YearIncrease/decrease for the Reporting Period as compared to the same period last year(From January to June)(%)EPS(RMB/share)0.42350.351420.52EPS Diluted(RMB/share)0.42320.350420.78Basic earnings per share after deducting the extraordinary gain or loss(RMB/share)0.42490.305738.99Weighted

46、 average return on net assets(%)6.656.04Increased by 0.61 percentage pointWeighted average return on net assets after deducting the extraordinary gain or loss(%)6.675.26Increased by 1.41 percentage pointsDescription of principal accounting data and financial indicators of the Company Applicable N/AA

47、t the end of the Reporting Period,the net profit attributable to Shareholders of the listed company after deducting the extraordinary gain or loss was RMB804 million,representing a year-on-year increase of 34.47%,mainly due to the growth of the sales revenues from the chemical pharmaceuticals and AP

48、Is products during the Reporting Period,which is the main driver of the growth of the net incomes.The net cash flow from operating activities was RMB1,903 million,representing a year-on-year increase of 155.16%,mainly due to an increase of cash collections of sales revenues during the Reporting Peri

49、od.VIII Differences in accounting data under domestic and foreign accounting standards Applicable N/A11Interim Report 2022IX Items and amounts of extraordinary gains and losses Applicable N/AUnit:YuanCurrency:RMBItems of Extraordinary Gains and LossesAmountsNotes(If applicable)Gains and losses on di

50、sposal of non-current assets3,731,885.55Proceeds from disposal of fixed assetsGovernment grants as included in the profit or loss of current period(Note:Government grants that are closely related to the normal business,in compliance with the relevant policies and continuously entitled with specific